Publications by authors named "Hong-Ming Yu"
Background: Preoperative hepatitis B virus (HBV) DNA level has been shown to correlate with the prognosis of patients with HBV-associated hepatocellular carcinoma (HCC) following liver resection, but its dynamic changes have not been reported. The aim of this longitudinal multicenter retrospective observational study was to describe the trajectory of HBV DNA after R0 liver resection in patients receiving antiviral therapy and to investigate its impact on clinical outcomes.
Methods: This study included patients with HBV-related HCC from nine hospitals in China who received antiviral therapy and R0 hepatectomy between 2015 and 2016.
Article Synopsis
- The study focuses on patients with hepatocellular carcinoma (HCC) without microvascular invasion (M0) and highlights the variability in their prognosis, sparking debate about the need for additional therapy after initial treatments like liver resection (LR) or liver transplantation (LT).
- Researchers developed the Eastern Hepatobiliary Surgery Hospital (EHBH)-M0 score using various clinical factors (including α-fetoprotein levels and tumor size) to classify these patients, revealing differing survival outcomes based on the score.
- The EHBH M0 scoring system proved to be more reliable than other existing staging systems in predicting patient prognosis, indicating that patients with higher scores could benefit from adjuvant therapies like transcatheter arterial
Article Synopsis
- Hepatocellular carcinoma (HCC) with microvascular invasion (MVI) has a high recurrence risk after liver surgery, prompting the exploration of adjuvant immunotherapy like sintilimab.
- A phase 2 trial involving 198 patients assessed the effectiveness and safety of sintilimab, comparing it to an active surveillance group, with a focus on recurrence-free survival (RFS) and overall survival (OS).
- Results showed significant improvements in RFS for the sintilimab group (27.7 months) versus active surveillance (15.5 months), with manageable side effects, suggesting promise for immune checkpoint inhibitors in high-risk HCC patients.
Background: The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment duration.
Methods: This retrospective study analyzed HCC patients who received sintilimab between January 2019 and December 2020 at four centers in China.
Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab.
View Article and Find Full Text PDFBackground: Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC).
Objectives: We investigated the efficacy and safety of atezolizumab, bevacizumab, and gemcitabine plus oxaliplatin (GEMOX) in advanced BTC and explore the potential biomarkers related to the response.
Design: Multicenter, single-arm, retrospective study.
Article Synopsis
- A study was conducted to compare the effectiveness and safety of three treatment options for unresectable recurrent hepatocellular carcinoma (HCC): transarterial chemoembolization combined with lenvatinib and PD-1 inhibitors (T-L-P), TACE with lenvatinib (T-L), and TACE alone.
- Among 204 patients analyzed, those in the T-L-P group had the best survival outcomes and disease control rates compared to the other two groups.
- The study concluded that the T-L-P regimen is both safe and significantly better in enhancing survival for patients dealing with unresectable recurrent HCC.
Background And Aims: The efficacy and safety of systemic atezolizumab and bevacizumab (atezo/bev) in treatment of patients with unresectable hepatocellular carcinoma (HCC) have been demonstrated. However, the efficacy of this treatment in patients with HCC and extrahepatic portal vein tumor thrombus (ePVTT) is not satisfactory. This study aimed to study the efficacy and safety of combining intensity-modulated radiotherapy (IMRT) with systemic atezo/bev in treatment of these patients.
View Article and Find Full Text PDFIntroduction: Vascular invasion and metastasis are poor prognostic factors in patients with hepatocellular carcinoma (HCC). The efficacy of available therapeutic regimens for unresectable HCC is not satisfactory in HCC with portal vein tumour thrombosis (PVTT). Therefore, this open-label, single-arm phase II clinical trial aims to investigate the efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating HCC patients with PVTT.
View Article and Find Full Text PDFThe therapeutic effect of transcatheter arterial chemoembolization (TACE) is limited for patients with hepatocellular carcinoma (HCC). Herein, we designed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety of TACE combined with atezolizumab plus bevacizumab for patients with Barcelona Clinic Liver Cancer (BCLC) stage-B HCC. Patients will initially receive TACE.
View Article and Find Full Text PDFAim: Surgical treatment is the first-line treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A1 hepatocellular carcinoma (HCC), and postoperative monitoring improves long-term survival. We aimed to establish a reasonable short-interval follow-up duration for patients with HCC.
Methods: The cohort for this retrospective study included 1396 HCC patients with BCLC stage 0 or A1 disease who underwent curative resection from 2013 to 2016 at five centers in China.
Article Synopsis
- The study compares the efficacy of two treatments for hepatocellular carcinoma (HCC): transarterial chemoembolization (TACE) combined with a PD-1 inhibitor versus TACE combined with a PD-1 inhibitor and lenvatinib.
- Results indicated that patients receiving the triple therapy had significantly better progression-free survival (PFS) and overall survival (OS) compared to those on the double therapy.
- While the triple therapy showed better clinical outcomes, it also had common treatment-related adverse events like decreased albumin and platelet count, but these were manageable.
Background And Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) who are refractory to transarterial chemoembolization (TACE) have a poor prognosis. This study aimed to explore whether stereotactic body radiation therapy (SBRT) combined with PD-1 inhibitors could improve the clinical outcomes of such patients.
Methods: This retrospective cohort study included patients with intermediate-stage HCC who were diagnosed with TACE refractoriness between January 2019 and December 2020 in the Eastern Hepatobiliary Surgery Hospital and the First Affiliated Hospital of Wenzhou Medical University.
Background: Microvascular invasion (MVI) is a prominent risk factor of postoperative recurrence for hepatocellular carcinoma (HCC). The MVI detection rate of conventional pathological examination approaches is relatively low and unsatisfactory.
Methods: By integrating pathological macro-slide with whole-mount slide imaging, we first created a novel pathological examination method called image-matching digital macro-slide (IDS).
Background: Microvascular invasion (MVI) is a significant risk factor affecting survival outcomes of patients after R0 liver resection (LR) for hepatocellular carcinoma (HCC). The current classification of MVI is not refined enough to prognosticate long-term survival of these patients, and a new MVI classification is needed.
Methods: Patients with HCC who underwent R0 LR at the Eastern Hepatobiliary Surgery Hospital from January 2013 to December 2013 and with resected specimens showing MVI were included in this study with an aim to establish a novel MVI classification.
Background: Microvascular invasion (MVI) is a significant risk factor affecting survival outcomes of patients after R0 liver resection (LR) for hepatocellular carcinoma (HCC). However, whether the existing staging systems of hepatocellular carcinoma can distinguish the prognosis of patients with MVI and the prognostic value of MVI in different subtypes of hepatocellular carcinoma remains to be clarified.
Methods: A dual-center retrospective data set of 1,198 HCC patients who underwent R0 LR was included in the study between 2014 and 2016.
A new strategy featuring an iridium-catalyzed asymmetric hydrogenation of a racemic ketone via dynamic kinetic resolution to generate a cyclopentanol with three contiguous stereocenters and a SmI2-promoted pinacol coupling to install the six-membered ring with correct stereochemistry has been described for the enantioselective total synthesis of (-)-hamigeran B (19 steps, 10.6% overall yield) and (-)-4-bromohamigeran B (19 steps, 12.3% overall yield).
View Article and Find Full Text PDFIn order to investigate the role of non-adrenergic non-cholinergic nerves in regulating mechanical and electrical activity of gastric circular smooth muscle, the effects of ATP and its analogues on gastric motility and electrical activities were observed in guinea-pig. In organ bath system, isometric force of the circular smooth muscle of guinea-pig gastric antrum was measured. Electrical activity of the muscle was recorded by using intracellular microelectrode.
View Article and Find Full Text PDFAim: To investigate the relationship between hyposmotic membrane stretch and muscarinic receptor agonist-induced depolarization of membrane potential in antral gastric circular myocytes of guinea-pig.
Methods: Using whole cell patch-clamp technique recorded membrane potential and current in single gastric myocytes isolated by collagenase.
Results: Hyposmotic membrane stretch hyperpolarized membrane potential from -60.